ACADIA Pharmaceuticals(ACAD) ZACKS·2024-11-12 15:56Core Insights - Zacks Premium offers tools for investors to enhance their stock market engagement and confidence [1] - The Zacks Style Scores are designed to complement the Zacks Rank, aiding in stock selection based on value, growth, and momentum [2][6] Zacks Style Scores Overview - Stocks are rated A, B, C, D, or F based on their value, growth, and momentum characteristics, with higher scores indicating better performance potential [3] - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score [3][4][5] Value Score - The Value Score identifies attractive and discounted stocks using ratios like P/E, PEG, Price/Sales, and Price/Cash Flow [3] Growth Score - The Growth Score focuses on a company's financial strength and future outlook, analyzing projected and historical earnings, sales, and cash flow [4] Momentum Score - The Momentum Score helps investors capitalize on price trends, utilizing factors like one-week price change and monthly earnings estimate changes [4] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator for stock selection based on value, growth, and momentum [5] Zacks Rank Integration - The Zacks Rank uses earnings estimate revisions to guide investors in portfolio creation, with 1 (Strong Buy) stocks yielding an average annual return of +25.41% since 1988 [6][7] - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal success [8] Acadia Pharmaceuticals (ACAD) Analysis - Acadia Pharmaceuticals is a biopharmaceutical company focused on CNS disorders and rare diseases, currently rated 3 (Hold) with a VGM Score of B [10] - The company has seen a 21.9% increase in shares over the past four weeks, with four analysts revising earnings estimates upwards for fiscal 2024 [10][11] - The Zacks Consensus Estimate for ACAD has risen by 0.58 per share, with an average earnings surprise of 54.1% [11]